X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Lupin Ltd with Orchid Chemicals - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN LTD vs ORCHID PHARMA LTD - Comparison Results

LUPIN LTD    Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

ORCHID PHARMA LTD 
   Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN LTD ORCHID PHARMA LTD LUPIN LTD/
ORCHID PHARMA LTD
 
P/E (TTM) x 23.0 -0.6 - View Chart
P/BV x 3.1 0.4 693.5% View Chart
Dividend Yield % 0.8 0.0 -  

Financials

 LUPIN LTD   ORCHID PHARMA LTD
EQUITY SHARE DATA
    LUPIN LTD
Mar-17
ORCHID PHARMA LTD
Sep-13
LUPIN LTD/
ORCHID PHARMA LTD
5-Yr Chart
Click to enlarge
High Rs1,750194 902.1%   
Low Rs1,38435 3,952.9%   
Sales per share (Unadj.) Rs387.4276.5 140.1%  
Earnings per share (Unadj.) Rs56.6-79.2 -71.5%  
Cash flow per share (Unadj.) Rs76.8-43.5 -176.8%  
Dividends per share (Unadj.) Rs7.500-  
Dividend yield (eoy) %0.50-  
Book value per share (Unadj.) Rs298.953.9 554.2%  
Shares outstanding (eoy) m451.5870.45 641.0%   
Bonus/Rights/Conversions ESOPSESOP-  
Price / Sales ratio x4.00.4 976.5%   
Avg P/E ratio x27.7-1.4 -1,913.8%  
P/CF ratio (eoy) x20.4-2.6 -773.8%  
Price / Book Value ratio x5.22.1 246.9%  
Dividend payout %13.20-   
Avg Mkt Cap Rs m707,5138,067 8,771.0%   
No. of employees `00016.82.8 599.7%   
Total wages/salary Rs m28,4952,527 1,127.6%   
Avg. sales/employee Rs Th10,418.36,956.1 149.8%   
Avg. wages/employee Rs Th1,697.0902.5 188.0%   
Avg. net profit/employee Rs Th1,523.0-1,993.0 -76.4%   
INCOME DATA
Net Sales Rs m174,94319,477 898.2%  
Other income Rs m1,065407 261.6%   
Total revenues Rs m176,00819,884 885.2%   
Gross profit Rs m44,9311,103 4,075.0%  
Depreciation Rs m9,1222,519 362.1%   
Interest Rs m1,5255,227 29.2%   
Profit before tax Rs m35,349-6,236 -566.8%   
Minority Interest Rs m-7220 -364.0%   
Prior Period Items Rs m830-   
Extraordinary Inc (Exp) Rs m0511 0.0%   
Tax Rs m9,785-125 -7,815.6%   
Profit after tax Rs m25,575-5,580 -458.3%  
Gross profit margin %25.75.7 453.7%  
Effective tax rate %27.72.0 1,378.8%   
Net profit margin %14.6-28.7 -51.0%  
BALANCE SHEET DATA
Current assets Rs m119,54211,014 1,085.3%   
Current liabilities Rs m61,20632,060 190.9%   
Net working cap to sales %33.3-108.1 -30.9%  
Current ratio x2.00.3 568.5%  
Inventory Days Days7695 80.1%  
Debtors Days Days9034 267.8%  
Net fixed assets Rs m131,66029,440 447.2%   
Share capital Rs m903705 128.2%   
"Free" reserves Rs m134,0732,043 6,563.8%   
Net worth Rs m134,9763,800 3,552.1%   
Long term debt Rs m56,4789,018 626.3%   
Total assets Rs m266,07346,510 572.1%  
Interest coverage x24.2-0.2 -12,518.1%   
Debt to equity ratio x0.42.4 17.6%  
Sales to assets ratio x0.70.4 157.0%   
Return on assets %10.2-0.8 -1,340.1%  
Return on equity %18.9-146.9 -12.9%  
Return on capital %19.3-3.7 -515.9%  
Exports to sales %037.9 0.0%   
Imports to sales %022.6 0.0%   
Exports (fob) Rs mNA7,378 0.0%   
Imports (cif) Rs mNA4,406 0.0%   
Fx inflow Rs m81,8857,513 1,089.9%   
Fx outflow Rs m21,5065,649 380.7%   
Net fx Rs m60,3781,865 3,238.3%   
CASH FLOW
From Operations Rs m41,1481,682 2,446.8%  
From Investments Rs m-25,287-9,860 256.4%  
From Financial Activity Rs m4,3326,644 65.2%  
Net Cashflow Rs m20,193-1,535 -1,315.5%  

Share Holding

Indian Promoters % 46.6 32.3 144.3%  
Foreign collaborators % 0.2 0.0 -  
Indian inst/Mut Fund % 11.3 4.6 245.7%  
FIIs % 31.9 3.3 966.7%  
ADR/GDR % 0.0 4.6 -  
Free float % 10.1 55.3 18.3%  
Shareholders   98,259 84,811 115.9%  
Pledged promoter(s) holding % 0.0 54.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN LTD With:   PIRAMAL ENTERPRISES  GSK PHARMA  PANACEA BIOTECH  DR. REDDYS LAB  NOVARTIS  

Compare LUPIN LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Marginally Higher; ONGC Rallies 6.3%(09:30 am)

Asian stock markets traded on a mixed note in morning trade as market participants kept an eye on political developments in the U.S. after a government shutdown began last week.

Related Views on News

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN LTD SHARE PRICE


Jan 22, 2018 11:27 AM

TRACK LUPIN LTD

  • Track your investment in LUPIN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

LUPIN LTD - ALEMBIC PHARMA COMPARISON

COMPARE LUPIN LTD WITH

MARKET STATS